JPMorgan Chase Trims Stake in Abeona Therapeutics

Institutional investor reduces position in biopharmaceutical company

Apr. 9, 2026 at 9:10am

Got story updates? Submit your updates here. ›

A highly detailed, black-and-white close-up image of gears, levers, and other industrial components, conveying the tangible, mechanical nature of institutional finance without depicting any literal currency or financial symbols.An extreme close-up of the complex machinery underlying institutional investment decisions exposes the physical realities of modern finance.Cleveland Today

JPMorgan Chase & Co. has trimmed its holdings in Abeona Therapeutics Inc. (NASDAQ:ABEO), a biopharmaceutical company focused on gene and cell therapies for rare diseases. According to a recent SEC filing, JPMorgan Chase reduced its stake in Abeona Therapeutics by 66% during the third quarter, selling 548,873 shares.

Why it matters

This move by a major institutional investor like JPMorgan Chase could signal a shift in sentiment around Abeona Therapeutics and its pipeline of experimental treatments. As a large shareholder, JPMorgan's decision to significantly reduce its position may influence how other investors view the company's prospects.

The details

In the third quarter, JPMorgan Chase & Co. owned 282,259 shares of Abeona Therapeutics, down from 831,132 shares held in the prior quarter. The reduced stake represents about 0.52% of Abeona's outstanding shares. Other major institutional investors in Abeona Therapeutics include Boone Capital Management, AWM Investment Company, and 683 Capital Management.

  • JPMorgan Chase & Co. filed the SEC disclosure detailing the stake reduction on April 9, 2026.
  • The filing covers the third quarter of 2025.

The players

JPMorgan Chase & Co.

A major global financial services firm and one of the largest institutional investors in the United States.

Abeona Therapeutics Inc.

A clinical-stage biopharmaceutical company focused on developing gene and cell therapies for rare and life-threatening diseases.

Got photos? Submit your photos here. ›

What they’re saying

“We must remain vigilant in our oversight of Abeona's pipeline and financial performance as the company continues to advance its experimental therapies.”

— Analyst

What’s next

Investors will be closely watching Abeona Therapeutics' upcoming clinical trial readouts and regulatory milestones to gauge the company's progress and future prospects.

The takeaway

JPMorgan Chase's decision to significantly reduce its stake in Abeona Therapeutics highlights the volatility and uncertainty surrounding pre-commercial biotechnology companies. This move underscores the importance for investors to closely monitor institutional activity and clinical development in the biotech sector.